Topics

Celgene’s blockbuster Revlimid fails in non-Hodgkin’s lymphoma DLBCL subtype

06:38 EDT 1 May 2019 | Pharmaceutical Technology

On 25 April, Celgene announced top-line results from its Phase III ROBUST trial evaluating Revlimid (lenalidomide) in diffuse large B-cell...
Read More...

The post Celgene’s blockbuster Revlimid fails in non-Hodgkin’s lymphoma DLBCL subtype appeared first on Pharmaceutical Technology.

Original Article: Celgene’s blockbuster Revlimid fails in non-Hodgkin’s lymphoma DLBCL subtype

NEXT ARTICLE

More From BioPortfolio on "Celgene’s blockbuster Revlimid fails in non-Hodgkin’s lymphoma DLBCL subtype"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...